

BIOGENIC AMINES AND PHYSIOLOGICAL MEMBRANES IN DRUG THERAPY

(in two parts)

PART B

Edited by

JOHN H. BIEL

DIRECTOR, DIVISION OF PHARMACOLOGY AND MEDICINAL CHEMISTRY
ABBOTT LABORATORIES, SCIENTIFIC DIVISIONS
NORTH CHICAGO, ILLINOIS

and

LEO G. ABOOD

CENTER FOR BRAIN RESEARCH AND DEPARTMENT OF BIOCHEMISTRY
UNIVERSITY OF ROCHESTER
ROCHESTER, NEW YORK

1971

MARCEL DEKKER, INC., NEW YORK

COPYRIGHT © 1971 by MARCEL DEKKER, INC.

ALL RIGHTS RESERVED

No part of this work may be reproduced or utilized in any form or by any means, electronic or mechanical, including xerography, photocopying, microfilm, and recording, or by any information storage and retrieval system, without permission in writing from the publisher.

MARCEL DEKKER, INC.

95 Madison Avenue, New York, New York 10016

LIBRARY OF CONGRESS CATALOG CARD NUMBER 77-180643

ISBN 0-8247-1030-4

PRINTED IN THE UNITED STATES OF AMERICA

*BIOGENIC AMINES
AND PHYSIOLOGICAL MEMBRANES
IN DRUG THERAPY*
(in two parts)

Part B

**MEDICINAL RESEARCH:
A SERIES OF MONOGRAPHS**

Consulting Editor: GARY L. GRUNEWALD

VOLUME 1: *Drugs Affecting the Peripheral Nervous System*, edited by Alfred Burger

VOLUME 2: *Drugs Affecting the Central Nervous System*, edited by Alfred Burger

VOLUME 3: *Selected Pharmacological Testing Methods*, edited by Alfred Burger

VOLUME 4: *Analytical Metabolic Chemistry of Drugs*, by Jean L. Hirtz

VOLUME 5: *Biogenic Amines and Physiological Membranes in Drug Therapy*,
Edited by John H. Biel and Leo G. Abood

In Preparation:

VOLUME 6: *Search for New Drugs*, Edited by Alan D. Rubin

CONTRIBUTORS TO PART B

C. R. Creveling, National Institute of Arthritis and Metabolic Diseases,
Bethesda, Maryland

John W. Daly, Laboratory of Chemistry, National Institute of Arthritis and
Metabolic Diseases, Bethesda, Maryland

O. Hornykiewicz, Department of Pharmacology, University of Toronto,
and Department of Psychopharmacology, Clarke Institute of Psychiatry,
University of Toronto, Canada

Leslie L. Iversen, Department of Pharmacology, University of Cambridge,
Cambridge, England

Donald M. Jerina, Laboratory of Chemistry, National Institute of Arthritis
and Metabolic Diseases, Bethesda, Maryland

Irwin J. Kopin, Laboratory of Clinical Science, National Institute of Mental
Health, Bethesda, Maryland

Richard W. Schayer, Research Center, Rockland State Hospital, Orange-
burg, New York

Bernhard Witkop, Laboratory of Chemistry, National Institute of Arthritis
and Metabolic Diseases, Bethesda, Maryland

CONTENTS OF PART A

The Role of Proteins and Lipids in Membrane Structure and Function,
Leo G. Aboud and Akira Matsubara, Center for Brain Research and
Department of Biochemistry, University of Rochester, Rochester,
New York

Biophysical Role of Na^+ , K^+ , Mg^{2+} -Activated Adenosine Triphosphatase
in Nerve Cell Membrane, Ryo Tanaka, Center for Brain Research,
University of Rochester, Rochester, New York

Nerve Excitation and "Phase Transition" in Membrane Macromolecules,
Ichiji Tasaki, Laboratory of Neurobiology, National Institute of Mental
Health, Bethesda, Maryland

Divalent Cation, Organic Cation, and Polycation Interaction with Excitable,
Thin Lipid Membranes, Ross C. Bean, William C. Shepherd, and
Joellen T. Eichner, Philco-Ford Corporation, Aeronutronic Division,
Newport Beach, California

CONTENTS

Contributors to Part B	iii
Contents of Part A	iv
5. Histamine and Its Role in Biological Systems	161
Richard W. Schayer	
I. Introduction.	162
II. Histamine Metabolism	162
III. Pharmacological Actions of Histamine	164
IV. Histamine and the Nervous System	165
V. Histamine and Microcirculatory Regulation	166
VI. Histamine and Glucocorticoid Action	168
VII. Conclusion	170
References	170
6. Dopamine: Its Physiology, Pharmacology, and Pathological Neurochemistry	173
O. Hornykiewicz	
I. Introduction	173
II. Occurrence of Dopamine in Different Tissues	176
III. Pharmacology of Dopamine.	192
IV. Brain Dopamine and the Pathophysiology of Parkinsonianism	225
V. Pharmacology of L-Dopa as an Antiparkinsonian Drug .	231
VI. Existence of a Specific Dopamine Receptor - Summary and Conclusions	240
References	242

7.	The Uptake of Biogenic Amines	259
	Leslie L. Iversen	
	I. Introduction	259
	II. The Uptake of Noradrenaline	261
	III. Other Amine Uptake Processes	311
	IV. Summary and Conclusions	318
	References	320
8.	False Neurotransmitters in the Mechanism of Action of Central Nervous System and Cardiovascular Drugs	329
	Irwin J. Kopin	
	I. Introduction	329
	II. Factors Contributing to False Transmitter Accumulation and Effects	330
	III. Role of False Transmitters in Drug Action	338
	IV. Conclusion	348
	References	349
9.	The Application of Biochemical Techniques in the Search for Drugs Affecting Biogenic Amines	355
	C. R. Creveling and J. W. Daly	
	I. Introduction	355
	II. Enzymatic Transformations of Biogenic Amines	356
	III. Transport, Storage, and Release of Biogenic Amines	384
	IV. Activity of Biogenic Amines	394
	References	398
10.	The "NIH Shift" and a Mechanism of Enzymatic Oxygenation	413
	Donald M. Jerina, John W. Daly, and Bernhard Witkop	
	I. Introduction	414
	II. Enzymatic Aryl Hydroxylation, Chemical Model Systems, and the NIH Shift	420
	III. Arene Oxides as Intermediates	451
	IV. A Mechanism for Monooxygenase Catalyzed Reactions	464

V. Conclusions	469
References	470
Author Index	477
Subject Index	513

